Metabolic Diseases: Type 2 Diabetes

Over the past decades the incidence of diabetes has progressively increased. According to the American Diabetes Association (ADA), diabetes affects more than 20 million people in the USA alone. Diabetes is associated with increased risk of a number of serious complications.

Prous Institute's research efforts are focused on developing novel, more effective and safer therapies for type 2 diabetes. One series of compounds was prepared as potent SGLT2 inhibitors. Three series of compounds are being developed as GPR119 agonists. Both classes of compounds work in a completely different way to any of the existing type 2 diabetes therapeutics. Representative compounds for each series include:

Compound      
Target / Action Status
 JRP 493
 SGLT2  / Inhibitor        
Preclinical, Patent application submitted
 JRP 1822 SGLT2  / Inhibitor
 Preclinical, Patent application submitted
 JRP 1604 GPR 119 / Agonist Lead Discovery
 

Type 2 diabetes is characterized as a proinflammatory and procoagulant condition. The high incidence of cardiovascular ischemic events in patients with type 2 diabetes is explained by the development of atherothrombotic lesions. Compounds JRP 493 and JRP 1822 have been proven to control glycemia and to have moderate platelet antiaggregatory activity.